Tags

Type your tag names separated by a space and hit enter

IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
Leukemia. 2013 Jan; 27(1):183-9.L

Abstract

To clarify the relationships between marginal zone lymphomas (MZLs) and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas (WM/LPLs), immunoglobulin heavy chain variable gene (IGHV) features were analyzed and the occurrence of MYD88 L265P mutations was identified in a series of 123 patients: 53 MZLs from the spleen (SMZLs), 11 from lymph nodes (NMZLs), 28 mucosa-associated lymphatic tissue (MALT) lymphomas and 31 WM/LPLs. SMZLs were characterized by overrepresentation of IGHV1-2 gene rearrangements with a canonical motif, without selection pressure and with long CDR3 segments. NMZLs had increased frequencies of IGHV3 genes. The IGHV gene was unmutated in most cases, often with long CDR3 segments. MALT lymphomas were usually associated with a mutated IGHV gene, but with the absence of selection pressure. WM/LPLs were associated with an IGHV3-23 overrepresentation and high IGHV mutation rate, with features of selection pressure and short CDR3 segments. MYD88 L265P mutations were almost restricted exclusively to WM/LPL patients. Taken all diagnoses together, all patients with MYD88 L265P mutations had an immunoglobulin M peak and almost all patients except one had bone marrow infiltration. These results demonstrate that the history of antigen exposure of the four entities studied was different and MYD88 L265P was specifically associated with WM/LPLs. WM/LPL may thus be functionally associated with constitutive nuclear factor-κB activation.

Authors+Show Affiliations

Laboratoires d'Hématologie et d'Immunologie, CHU de Limoges, Limoges and Centre National de la Recherche Scientifique, UMR CNRS 7276, Faculté de Médecine de Limoges, Université de Limoges, Limoges, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22944768

Citation

Gachard, N, et al. "IGHV Gene Features and MYD88 L265P Mutation Separate the Three Marginal Zone Lymphoma Entities and Waldenström Macroglobulinemia/lymphoplasmacytic Lymphomas." Leukemia, vol. 27, no. 1, 2013, pp. 183-9.
Gachard N, Parrens M, Soubeyran I, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia. 2013;27(1):183-9.
Gachard, N., Parrens, M., Soubeyran, I., Petit, B., Marfak, A., Rizzo, D., Devesa, M., Delage-Corre, M., Coste, V., Laforêt, M. P., de Mascarel, A., Merlio, J. P., Bouabdhalla, K., Milpied, N., Soubeyran, P., Schmitt, A., Bordessoule, D., Cogné, M., & Feuillard, J. (2013). IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia, 27(1), 183-9. https://doi.org/10.1038/leu.2012.257
Gachard N, et al. IGHV Gene Features and MYD88 L265P Mutation Separate the Three Marginal Zone Lymphoma Entities and Waldenström Macroglobulinemia/lymphoplasmacytic Lymphomas. Leukemia. 2013;27(1):183-9. PubMed PMID: 22944768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. AU - Gachard,N, AU - Parrens,M, AU - Soubeyran,I, AU - Petit,B, AU - Marfak,A, AU - Rizzo,D, AU - Devesa,M, AU - Delage-Corre,M, AU - Coste,V, AU - Laforêt,M P, AU - de Mascarel,A, AU - Merlio,J P, AU - Bouabdhalla,K, AU - Milpied,N, AU - Soubeyran,P, AU - Schmitt,A, AU - Bordessoule,D, AU - Cogné,M, AU - Feuillard,J, Y1 - 2012/09/04/ PY - 2012/9/5/entrez PY - 2012/9/5/pubmed PY - 2013/3/1/medline SP - 183 EP - 9 JF - Leukemia JO - Leukemia VL - 27 IS - 1 N2 - To clarify the relationships between marginal zone lymphomas (MZLs) and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas (WM/LPLs), immunoglobulin heavy chain variable gene (IGHV) features were analyzed and the occurrence of MYD88 L265P mutations was identified in a series of 123 patients: 53 MZLs from the spleen (SMZLs), 11 from lymph nodes (NMZLs), 28 mucosa-associated lymphatic tissue (MALT) lymphomas and 31 WM/LPLs. SMZLs were characterized by overrepresentation of IGHV1-2 gene rearrangements with a canonical motif, without selection pressure and with long CDR3 segments. NMZLs had increased frequencies of IGHV3 genes. The IGHV gene was unmutated in most cases, often with long CDR3 segments. MALT lymphomas were usually associated with a mutated IGHV gene, but with the absence of selection pressure. WM/LPLs were associated with an IGHV3-23 overrepresentation and high IGHV mutation rate, with features of selection pressure and short CDR3 segments. MYD88 L265P mutations were almost restricted exclusively to WM/LPL patients. Taken all diagnoses together, all patients with MYD88 L265P mutations had an immunoglobulin M peak and almost all patients except one had bone marrow infiltration. These results demonstrate that the history of antigen exposure of the four entities studied was different and MYD88 L265P was specifically associated with WM/LPLs. WM/LPL may thus be functionally associated with constitutive nuclear factor-κB activation. SN - 1476-5551 UR - https://www.unboundmedicine.com/medline/citation/22944768/IGHV_gene_features_and_MYD88_L265P_mutation_separate_the_three_marginal_zone_lymphoma_entities_and_Waldenström_macroglobulinemia/lymphoplasmacytic_lymphomas_ L2 - http://dx.doi.org/10.1038/leu.2012.257 DB - PRIME DP - Unbound Medicine ER -